Stoke Therapeutics extends headquarters lease to Dec 2026; aggregate rent ~$5.05M

Stoke Therapeutics, Inc.

Entered first amendment to lease for corporate HQ and lab at 45-47 Wiggins Ave, Bedford, MA.
Lease term extended by two years to December 31, 2026.
Aggregate estimated base rent over extension period approximately $5.05 million.
Option to further extend for five years at 95% of then-prevailing market rate.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Stoke Therapeutics, Inc. amended First Amendment with Xenon Property, LLC valued at approximately $5.05 million (effective 2023-12-12).

Action: amendment
Agreement: lease
Counterparty: Xenon Property, LLC
Value: approximately $5.05 million
Effective: 2023-12-12

Exact text from the filing

On December 12, 2023, Stoke Therapeutics, Inc. (the “ Company ”) entered into a first amendment (the “ First Amendment ”) to its corporate headquarters and laboratory lease agreement with Xenon Property, LLC, as successor-in-interest to ARE-MA Region No. 24, LLC, located at 45-47 Wiggins Avenue, Bedford, Massachusetts (the “ Lease ”), in order to extend the term of the Lease for a period of two years (the “ Lease Extension Period ”).

View on SEC.gov

Browse all material agreements →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-295456

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.